Bone Marrow Health, Leukemia Risk, and Monitoring
At a Glance
Emberger syndrome linked to GATA2 deficiency can weaken blood-forming stem cells and reduce blood cell production. Regular blood counts and marrow tests help specialists find chromosome or mutation changes early, assess the risk of myelodysplastic syndrome and leukemia, and guide transplant decisions.
While the hearing loss and swelling associated with Emberger syndrome are characteristic signs, a critical part of the condition happens inside the bone marrow. In GATA2 deficiency, the bone marrow is often described as “unstable” [1]. Understanding how doctors monitor this instability is key to protecting long-term health.
The Bone Marrow “Factory”
Your bone marrow is like a factory that produces all the blood cells the body needs. This process is led by Hematopoietic Stem Cells (HSCs)—the “seed” cells that can turn into any type of blood cell [2][3].
In GATA2 deficiency, the pathogenic variant affects these stem cells. They struggle to copy themselves and age prematurely [4][5]. Over time, this leads to hypocellularity, which means the bone marrow factory is under-staffed and cannot produce enough healthy cells [1][6]. When the marrow can no longer function correctly, it can lead to Myelodysplastic Syndrome (MDS) or progress into Acute Myeloid Leukemia (AML) [7][8].
Understanding Clonal Evolution
Doctors use the term clonal evolution to describe how the bone marrow changes over time [9]. In GATA2 deficiency, a cell may start to copy itself more successfully than the others, creating a “clone” [10]. This process can happen even if your blood counts seem relatively stable [11]. Detecting these changes early is the primary goal of regular monitoring.
Red Flag Markers in the Marrow
During a biopsy (a procedure where a small sample of bone marrow is taken for testing), specialists look for specific “red flags” [12].
Chromosomal Changes (Cytogenetics)
Doctors look at the structure of the chromosomes within the marrow cells:
- Monosomy 7: This is when a cell is missing one of its two “number 7” chromosomes. It is one of the most common and concerning markers in GATA2 deficiency [7][13].
- Trisomy 8: This is when a cell has an extra “number 8” chromosome [13].
Somatic Mutations
As the bone marrow tries to compensate, it may pick up new, “acquired” mutations that were not present at birth. These are called somatic mutations [14].
Mutations in genes like ASXL1, STAG2, SETBP1, RUNX1, or the RAS pathway are often seen during bone marrow changes [14][13][15].
It is important to understand that a somatic mutation or cytogenetic clone does not by itself establish imminent leukemia. Morphology, blast percentage (the percentage of immature blood-forming cells), cytopenias, cytogenetics, and molecular results must be interpreted together by a specialist. These changes do not follow a fixed stepwise sequence.
Individualized Surveillance
Because bone marrow changes can be “silent,” periodic check-ups are the only way to catch them [16]. While every medical center has its own protocol, many experts use:
- Periodic Blood Counts: Regular blood tests to monitor levels of hemoglobin, platelets, and white blood cells [17].
- Periodic Marrow Exams: A baseline bone marrow aspirate and biopsy to check for hypocellularity, dysplasia (abnormal-looking cells), and genetic markers. While many expert protocols use an annual marrow exam, the interval depends entirely on the patient’s age, counts, symptoms, prior findings, and the center’s practices [17][18].
- Increased Frequency: If a new clone or chromosomal change is found, your doctor will likely want to perform tests much more often [19][14].
The Goal of Monitoring
The ultimate goal of this monitoring is to identify the best strategy for treatment, which may include a stem cell transplant. Research shows that patients have better outcomes when intervention happens before the disease turns into advanced leukemia [16][20]. By staying diligent with monitoring, you are helping the care team act at the safest possible moment [21].
Common questions in this guide
How does GATA2 deficiency affect the bone marrow?
What does clonal evolution mean in GATA2 deficiency?
What do monosomy 7 and trisomy 8 mean on a bone marrow report?
Do acquired mutations such as ASXL1 or STAG2 mean that I have leukemia?
How often are blood counts and bone marrow biopsies needed in GATA2 deficiency?
Why is regular monitoring important if blood counts are stable?
What changes should a person with GATA2 deficiency report to the care team?
One line in your results can change your plan.
A new clone or chromosomal change found on marrow testing will likely prompt your doctor to test much more often. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on Deafness-lymphedema-leukemia syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (21)
- 1
GATA 2 Deficiency: Focus on Immune System Impairment.
Fabozzi F, Mastronuzzi A, Ceglie G, et al.
Frontiers in immunology 2022; (13()):865773 doi:10.3389/fimmu.2022.865773.
PMID: 35769478 - 2
Sequencing of RNA in single cells reveals a distinct transcriptome signature of hematopoiesis in GATA2 deficiency.
Wu Z, Gao S, Diamond C, et al.
Blood advances 2020; (4(12)):2656-2670 doi:10.1182/bloodadvances.2019001352.
PMID: 32556286 - 3
GATA2 deficiency and related myeloid neoplasms.
Wlodarski MW, Collin M, Horwitz MS
Seminars in hematology 2017; (54(2)):81-86 doi:10.1053/j.seminhematol.2017.05.002.
PMID: 28637621 - 4
CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.
Romero-Moya D, Torralba-Sales E, Calvo C, et al.
Leukemia 2025; (39(12)):3015-3025 doi:10.1038/s41375-025-02771-8.
PMID: 40954215 - 5
GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome.
Largeaud L, Fregona V, Jamrog LA, et al.
Blood cancer journal 2025; (15(1)):7 doi:10.1038/s41408-025-01213-z.
PMID: 39885120 - 6
miR-181c regulates MCL1 and cell survival in GATA2 deficient cells.
Wang W, Chen R, Droll S, et al.
Journal of leukocyte biology 2022; (111(4)):805-816 doi:10.1002/JLB.2A1220-824R.
PMID: 34270823 - 7
GATA2 Deficiency: Predisposition to Myeloid Malignancy and Hematopoietic Cell Transplantation.
Rajput RV, Arnold DE
Current hematologic malignancy reports 2023; (18(4)):89-97 doi:10.1007/s11899-023-00695-7.
PMID: 37247092 - 8
GATA2 deficiency syndrome: A decade of discovery.
Homan CC, Venugopal P, Arts P, et al.
Human mutation 2021; (42(11)):1399-1421 doi:10.1002/humu.24271.
PMID: 34387894 - 9
MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.
McReynolds LJ, Yang Y, Yuen Wong H, et al.
Leukemia research 2019; (76()):70-75 doi:10.1016/j.leukres.2018.11.013.
PMID: 30578959 - 10
ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome.
West RR, Calvo KR, Embree LJ, et al.
Blood advances 2022; (6(3)):793-807 doi:10.1182/bloodadvances.2021005065.
PMID: 34529785 - 11
Rapid progression to AML in a patient with germline GATA2 mutation and acquired NRAS Q61K mutation.
McReynolds LJ, Zhang Y, Yang Y, et al.
Leukemia research reports 2019; (12()):100176 doi:10.1016/j.lrr.2019.100176.
PMID: 31245276 - 12
Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications.
Kallen ME, Dulau-Florea A, Wang W, Calvo KR
Seminars in hematology 2019; (56(1)):69-82 doi:10.1053/j.seminhematol.2018.05.016.
PMID: 30573048 - 13
Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiency.
Kotmayer L, Kozyra EJ, Kang G, et al.
Blood cancer journal 2025; (15(1)):121 doi:10.1038/s41408-025-01309-6.
PMID: 40664679 - 14
Somatic genetic alterations predict hematological progression in GATA2 deficiency.
Largeaud L, Collin M, Monselet N, et al.
Haematologica 2023; (108(6)):1515-1529 doi:10.3324/haematol.2022.282250.
PMID: 36727400 - 15
Germline and somatic genetic landscape of pediatric myelodysplastic syndromes.
Kotmayer L, Kennedy AL, Wlodarski MW
Haematologica 2025; (110(9)):1974-1986 doi:10.3324/haematol.2024.285700.
PMID: 40568716 - 16
Long-term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium.
Sicre de Fontbrune F, Chevillon F, Fahd M, et al.
British journal of haematology 2026; (208(1)):250-258 doi:10.1111/bjh.19691.
PMID: 39159950 - 17
Monitoring and treatment of MDS in genetically susceptible persons.
Davies SM
Hematology. American Society of Hematology. Education Program 2019; (2019(1)):105-109 doi:10.1182/hematology.2019000020.
PMID: 31808891 - 18
Inherited bone marrow failure syndromes and germline predisposition to myeloid neoplasia: A practical approach for the pathologist.
Li J, Bledsoe JR
Seminars in diagnostic pathology 2023; (40(6)):429-442 doi:10.1053/j.semdp.2023.06.006.
PMID: 37507252 - 19
The different faces of GATA2 deficiency: implications for therapy and surveillance.
Vinci L, Strahm B, Speckmann C, Erlacher M
Frontiers in oncology 2024; (14()):1423856 doi:10.3389/fonc.2024.1423856.
PMID: 38993648 - 20
Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome.
Bortnick R, Wlodarski M, de Haas V, et al.
Bone marrow transplantation 2021; (56(11)):2732-2741 doi:10.1038/s41409-021-01374-y.
PMID: 34244664 - 21
Successful reduced-intensity stem cell transplantation for GATA2 deficiency before progression of advanced MDS.
Saida S, Umeda K, Yasumi T, et al.
Pediatric transplantation 2016; (20(2)):333-6 doi:10.1111/petr.12667.
PMID: 26748574
This page is for informational purposes only and does not constitute medical advice. A hematology team should interpret your blood counts, bone marrow biopsy, and genetic findings and set an individualized monitoring plan.